NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
19.16
+9.70 (102.54%)
At close: Jan 9, 2026, 4:00 PM EST
20.50
+1.34 (6.99%)
After-hours: Jan 9, 2026, 8:00 PM EST
Company Description
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products.
The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions.
It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Michael Kazley |
Contact Details
Address: 2000 Powell Street, Suite 1150, eleventh floor Emeryville, California 94608 United States | |
| Phone | 510 899 8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P4090 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Kazley | Chief Executive Officer and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2025 | EFFECT | Notice of Effectiveness |
| Nov 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 25, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 21, 2025 | 8-K | Current Report |
| Oct 20, 2025 | SCHEDULE 13D/A | Filing |
| Oct 20, 2025 | SCHEDULE 13D/A | Filing |
| Oct 20, 2025 | 8-K | Current Report |
| Oct 17, 2025 | SCHEDULE 13D/A | Filing |